-
-
-
-
-
-
-
Zymeworks raises 2026 guidance after closing Theravance acquisition
-
-
-
-
-
-
-
B. Riley: 'Aggressively Buying the ZYME Dip'
-
-
-
-
-
-
-
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Zymeworks shifts strategy to focus on royalty-driven growth model
-
-
-
-
-
-
-
Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
-
1,201,799 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


